TNF and ulcerative colitis: Monoclonal antibodies against tumor necrosis factor alpha (TNFα), such as infliximab (IFX) or adalimumab (ADA), are safe and effective in induction and maintenance of remission in moderate to severe pediatric Crohn’s disease (CD) and ulcerative colitis (UC) patients [5,6].